Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)
This trial will be split into two sub-studies. In Sub-Study A, eligible participants will receive subcutaneous Sasanlimab in combination with oral Encorafenib & Binimetinib. In Sub-Study B, eligible participants will receive subcutaneous Sasanlimab in combination with oral Axitinib and intravenous SEA-TGT. In both sub-studies, treatment will be administered until progressive disease, unacceptable adverse event, the patient withdraws, or the study is terminated.